9:22 AM
Leo Group India
| ||
| Last Chance For A Bargain On Isis Pharmaceuticals? Seeking Alpha Holding Isis Pharmaceuticals (ISIS) has been a wild ride this year. As recently as April, it was down near $7 a share. Then recently, as the FDA advisory committee meeting for its familial hypercholesterolemia drug Kynamro approached, the stock went ... See all stories on this topic » | ||
| Alexza Pharmaceuticals' Staccato® Technology Receives Frost & Sullivan ... Sacramento Bee MOUNTAIN VIEW, Calif., Oct. 18, 2012 -- /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that based on Frost & Sullivan's recent analysis of the bipolar disorder therapeutics market, they are recognizing Alexza ... See all stories on this topic » | ||
| Avion Pharmaceuticals, LLC, featured on Lifetime® Television Network's The ... Sacramento Bee ATLANTA, Oct. 18, 2012 -- /PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced its partnership with The Balancing Act®, a daily morning talk show on the Lifetime® Television Network devoted to supporting ... See all stories on this topic » | ||
| WebMD losing advertisers, in need of a makeover Times of India Parents worried about their toddlers have long turned to the WebMD website to check symptoms, but the popular site now needs a doctor itself as WebMD Health Corp suffers from a fall in advertising by budget-slashing pharmaceutical companies. See all stories on this topic » | ||
| Cubist Pharmaceutical's Management Discusses Q3 2012 Results - Earnings ... Seeking Alpha Good afternoon and thank you for joining us for our review of third quarter 2012 business performance and financial results for Cubist Pharmaceuticals. Before introducing our speakers, I will read the Safe Harbor Statement and describe the context for ... See all stories on this topic » | ||
| Liverpool pharmaceuticals firm receives £4.7 RGF money bdaily Liverpool early stage drug development company, Redx Pharma has received £4.7m of regional growth fund money. The University of Liverpool based firm will use the money to fund an initial two-year pre-clinical phase of a five year research and ... See all stories on this topic » | ||
| Cumberland Pharmaceuticals to Announce Third Quarter 2012 Financial Results ... Sacramento Bee NASHVILLE, Tenn., Oct. 18, 2012 -- /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2012 results after the market closes on Thursday, November 1, 2012. A conference call and live Internet ... See all stories on this topic » | ||
| Committee to resolve issues of pharmaceutical industry The News International The Drug Regulatory Agency of Pakistan (DRAP) has decided to establish a committee to resolve the long outstanding issues being faced by the pharmaceutical sector, including a considerable increase in fee structure of services offered by DRAP, huge ... See all stories on this topic » | ||
| Alembic Pharma will add more specialty product, Q2 net profit up 12% Economic Times AHMEDABAD: Vadodara-headquartered drug maker Alembic Pharmaceuticals said it will add more to the basket of specialty products for growth after its net profit rise 12% in its Q2 net profit. The company's recently launched dermatology division has shown ... See all stories on this topic » | ||
| DECHRA PHARMACEUTICALS PLC : Interim Management Statement and ... 4-traders 15 year tenure, Dechra has developed into a significant veterinary pharmaceutical business in which the challenges and opportunities for a Group Finance Director are considerable. Simon recognises that following the acquisitions of Eurovet and Vetxx ... See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment